Timber Pharmaceuticals, Inc. (TMBR) is a publicly traded company in the Unknown sector. Across all available filings, 9 corporate insiders have executed 42 transactions totaling $2.3M, demonstrating a bearish sentiment with -$2.3M in net insider flow. The most recent transaction on Aug 20, 2023 involved a transaction of 35,193 shares valued at $0.
No significant insider buying has been recorded for TMBR in the recent period.
No significant insider selling has been recorded for TMBR in the recent period.
Based on recent SEC filings, insider sentiment for TMBR is bearish with an Insider Alignment Score of 1/100 and a net flow of -$2.3M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at Timber Pharmaceuticals, Inc. (TMBR) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 9 insiders are actively trading TMBR stock, having executed 42 transactions in the past 90 days. The most active insider is Sciences Llc Tardimed (Executive), who has made 24 transactions totaling $2.3M.
Get notified when executives and directors at TMBR file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Aug 20, 2023 | Lucchese Joseph | Executive | Award | 35,193 | $N/A | $0 | |
| Aug 20, 2023 | Mendelsohn Alan | Executive | Award | 35,193 | $N/A | $0 | |
| Aug 20, 2023 | Koconis John | Executive | Award | 70,385 | $N/A | $0 | |
| Apr 15, 2023 | E. Cohen David | Executive | Award | 4,100 | $N/A | $0 | |
| Apr 15, 2023 | J. Sitar Edward | Executive | Award | 5,327 | $N/A | $0 | |
| Apr 15, 2023 | Pirozzi Gianluca | Executive | Award | 4,100 | $N/A | $0 | |
| Apr 15, 2023 | Gaal Lubor | Executive | Award | 4,100 | $N/A | $0 | |
| Dec 15, 2022 | J. Sitar Edward | Executive | Award | 2,500 | $1.63 | $4.1K | |
| Apr 15, 2022 | Gaal Lubor | Executive | Award | 100,000 | $N/A | $0 | |
| Apr 15, 2022 | Pirozzi Gianluca | Executive | Award | 100,000 | $N/A | $0 | |
| Apr 15, 2022 | J. Sitar Edward | Executive | Award | 150,000 | $N/A | $0 | |
| Apr 15, 2022 | E. Cohen David | Executive | Award | 100,000 | $N/A | $0 | |
| Mar 4, 2022 | Rome Zachary | Executive | Payment | 19,630 | $0.28 | $5.5K | |
| Mar 4, 2022 | Rome Zachary | Executive | Option Exercise | 79,326 | $N/A | $0 | |
| Dec 15, 2021 | Koconis John | Executive | Purchase | 20,000 | $0.38 | $7.6K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 23 | $2.3M | 98.6% |
Purchase(P) | 4 | $23.5K | 1.0% |
Payment(F) | 1 | $5.5K | 0.2% |
Award(A) | 12 | $4.1K | 0.2% |
Exercise(M) | 1 | $0 | 0.0% |
Other(J) | 1 | $0 | 0.0% |
Insider selling pressure at Timber Pharmaceuticals, Inc. has increased, with 9 insiders executing 42 transactions across all time. Total sales of $2.3M significantly outpace purchases of $23.5K, resulting in a net outflow of $2.3M. This selling activity appears largely discretionary, which may warrant closer attention from investors.